Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NantBioscience

2013 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$205M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of molecularly targeted drugs. The company helps in discovering new compounds that are targeted at tumor signaling pathways in patients with specific genetic mutations.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 9920 Jefferson Boulevard
  • Culver City, CA 90232
  • United States

+1 (310) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NantBioscience’s full profile, request a free trial.

NantBioscience Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-Jun-2015 $205M 00000 00000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NantBioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.0 000 000 00 000 00.000
To view this company’s complete Cap Table, request access »

NantBioscience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Celgene Corporation Minority 000 0000 000000 0

NantBioscience Executive Team (1)

Name Title Board
Seat
Contact
Info
Patrick Soon-Shiong MD Founder & Chief Executive Officer